Excess mortality in middle-aged men with diabetes aged 15–34 years at diagnosis
- 98 Downloads
The aim of this study is to assess mortality risk and the excess of risk in patients with diabetes. Patients were 15–34 years old at diagnosis of diabetes mellitus (n = 879) in 1992 and 1993 in this national cohort from Sweden. Healthy controls were matched for gender and birth on the same day as the index cases (n = 837). The civic registration number was used to link patients and controls to the Swedish Cause of Death Registry. During follow-up, 3.3% (29/879) of patients and 1.1% (9/837; P = 0.002) of controls died. The risk for a patient with diabetes to die was almost threefold increased compared with healthy controls; hazard ratio, 2.9 (95% CI 1.4–6.2). This increased risk was significant in men; hazard ratio, 2.8 (95% CI 1.2–6.5). Diabetes as the underlying cause of death accounted for 38% (11/29) of deaths among patients. Most patients, 55% (16/29), died at home, remaining patients in hospital, 28% (8/29), or elsewhere 17% (5/29) compared to controls of whom 33% (3/9; P = 0.45) died at home, 33% (3/9; P = 1.0) in hospital, and 33% (3/9; P = 0.36) elsewhere. Only 55% (16/29) of patients had a specified day of death on death certificates compared to 100% (9/9; P = 0.016) of controls. Adult men with diabetes had an almost threefold increased risk to die within 15 years of diagnosis compared to healthy men. Most middle-aged patients with diabetes died at home and often without a specified date of death recorded.
KeywordsMortality Natural history Risk analysis Retrospective case–control study
This study was funded by The Crafoord Foundation, Lund, Sweden by a research grant (20080671) to CT. The present members of the DISS-study group are Hans Arnquist, Linköping, Jan Bolinder, Stockholm, Mona Landin-Olsson, Lund, Olov Rolandsson, Umeå, Soffia Gudbjörnsdottir (President), Gothenburg and Lennarth Nyström, Umeå. The baseline study from onset of diabetes and the first 6 years of disease with yearly blood sampling as well as the matched control study was funded by National Institutes of Health, NIH grant DK 42,654 to Åke Lernmark, Malmö, Sweden. Abstracts of less than 300 words were submitted to the 45th Annual Meeting of the Scandinavian Society for the Study of Diabetes (SSSD) 6–8 May 2010 and to the 46th EASD Annual Meeting 20–24 September 2010.
Conflict of interest statement
The authors of this manuscript declare no conflicts of interests.
- 1.Wibell L, Nystrom L, Ostman J, Arnqvist H, Blohme G, Lithner F, Littorin B, Sundkvist G (2001) Increased mortality in diabetes during the first 10 years of the disease. A population-based study (DISS) in Swedish adults 15–34 years old at diagnosis. J Intern Med 249:263–270PubMedCrossRefGoogle Scholar
- 5.Patterson CC, Dahlquist G, Harjutsalo V, Joner G, Feltbower RG, Svensson J, Schober E, Gyurus E, Castell C, Urbonaite B, Rosenbauer J, Iotova V, Thorsson AV, Soltesz G (2007) Early mortality in EURODIAB population-based cohorts of type 1 diabetes diagnosed in childhood since 1989. Diabetologia 50:2439–2442PubMedCrossRefGoogle Scholar
- 10.Torn C, Landin-Olsson M, Lernmark A, Palmer JP, Arnqvist HJ, Blohme G, Lithner F, Littorin B, Nystrom L, Schersten B, Sundkvist G, Wibell L, Ostman J (2000) Prognostic factors for the course of beta cell function in autoimmune diabetes. J Clin Endocrinol Metab 85:4619–4623PubMedCrossRefGoogle Scholar
- 11.Torn C, Landin-Olsson M, Ostman J, Schersten B, Arnqvist H, Blohme G, Bjork E, Bolinder J, Eriksson J, Littorin B, Nystrom L, Sundkvist G, Lernmark A (2000) Glutamic acid decarboxylase antibodies (GADA) is the most important factor for prediction of insulin therapy within 3 years in young adult diabetic patients not classified as Type 1 diabetes on clinical grounds. Diabetes Metab Res Rev 16:442–447PubMedCrossRefGoogle Scholar
- 12.Torn C, Landin-Olsson M, Lernmark A, Schersten B, Ostman J, Arnqvist HJ, Bjork E, Blohme G, Bolinder J, Eriksson J, Littorin B, Nystrom L, Sundkvist G (2001) Combinations of beta cell specific autoantibodies at diagnosis of diabetes in young adults reflects different courses of beta cell damage. Autoimmunity 33:115–120PubMedCrossRefGoogle Scholar
- 13.Diabetes Mellitus (1985) Report of a WHO study group. Technical report series No 727, Geneva. Google Scholar
- 15.Soedamah-Muthu SS, Fuller JH, Mulnier HE, Raleigh VS, Lawrenson RA, Colhoun HM (2006) All-cause mortality rates in patients with type 1 diabetes mellitus compared with a non-diabetic population from the UK general practice research database, 1992–1999. Diabetologia 49:660–666PubMedCrossRefGoogle Scholar
- 22.Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, Atreja A, Zimmerman RS (2009) The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis. Acta Diabetol 46:145–154PubMedCrossRefGoogle Scholar
- 23.Wit MA, de Mulder M, Jansen EK, Umans VA (2010) Diabetes mellitus and its impact on long-term outcomes after coronary artery bypass graft surgery. Acta Diabetol [Epub ahead of print] PubMed PMID: 20857149Google Scholar
- 24.May O, Arildsen H (2011) Long-term predictive power of heart rate variability on all-cause mortality in the diabetic population. Acta Diabetol 48:55–59Google Scholar
- 26.Marini MA, Frontoni S, Mineo D, Bracaglia D, Cardellini M, De Nicolais P, Baroni A, D’Alfonso R, Perna M, Lauro D, Federici M, Gambardella S, Lauro R, Sesti G (2003) The Arg972 variant in insulin receptor substrate-1 is associated with an atherogenic profile in offspring of type 2 diabetic patients. J Clin Endocrinol Metab 88:3368–3371PubMedCrossRefGoogle Scholar
- 28.Perticone F, Sciacqua A, Scozzafava A, Ventura G, Laratta E, Pujia A, Federici M, Lauro R, Sesti G (2004) Impaired endothelial function in never-treated hypertensive subjects carrying the Arg972 polymorphism in the insulin receptor substrate-1 gene. J Clin Endocrinol Metab 89:3606–3609PubMedCrossRefGoogle Scholar
- 29.Sesti G, Marini MA, Cardellini M, Sciacqua A, Frontoni S, Andreozzi F, Irace C, Lauro D, Gnasso A, Federici M, Perticone F, Lauro R (2004) The Arg972 variant in insulin receptor substrate-1 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. Diabetes Care 27:1394–1398PubMedCrossRefGoogle Scholar
- 32.Littorin B, Sundkvist G, Nystrom L, Carlson A, Landin-Olsson M, Ostman J, Arnqvist HJ, Bjork E, Blohme G, Bolinder J, Eriksson JW, Schersten B, Wibell L (2001) Family characteristics and life events before the onset of autoimmune type 1 diabetes in young adults: a nationwide study. Diabetes Care 24:1033–1037PubMedCrossRefGoogle Scholar